Hatteras Venture Partners
VC Fund
Durham, United States
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
- Total investments:
- 142
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Hatteras Venture Partners invests in
Stages Hatteras Venture Partners invests in
Countries Hatteras Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Series A
- $2.6M–$50M
- Series B
- $5M–$82M
- Series C
- $8M–$88M
Investment Focus
Industry
- Health Care 49 (35%)
- Biotechnology 43 (30%)
- Medical 25 (18%)
- Therapeutics 22 (15%)
- Medical Device 18 (13%)
Stage
- Series A 41 (29%)
- Series B 31 (22%)
- Series C 14 (10%)
- Venture - Series Unknown 11 (8%)
- Seed 8 (6%)
Country
- United States 73 (51%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Douglas Reed
General Partner
|
General Partner | Total investments: 8 | Find email | |
Jeff Terrell
General Partner
|
General Partner | Total investments: 10 | Find email | |
Myla Lai-Goldman
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Christy L. Shaffer
General Partner
|
General Partner | Total investments: 11 | Find email | |
Clay B. Thorp
General Partner and Co-Founder
|
General Partner and Co-Founder | Total investments: 14 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M / Series B / Jul 16, 2026 | ||
| 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $12M / Venture - Series Unknown / Jul 14, 2026 | ||
| Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy. | $7M / Seed / Jun 23, 2026 | ||
| Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M / Series B / May 14, 2026 | ||
| Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $5M / Series B / Apr 08, 2026 | ||
| Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | ||
| Pharaoh Neuro develops a neurapheresis cerebrospinal fluid management system for neurological patients. | $20M / Series A / Feb 18, 2026 | ||
| iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations. | Venture - Series Unknown / Nov 04, 2025 | ||
| Boomerang Medical is a female-led bioelectronic medical technology firm that is revolutionizing the management of autoimmune illnesses. | $20M / Series B / Sep 04, 2025 | ||
| Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines. Founded in 2021, the company is based in Boston, Massachusetts. | $25M / Series A / Aug 29, 2025 | ||
| See all 142 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Hatteras Venture Partners invest in?
Hatteras Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 142 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hatteras Venture Partners's check size?
Hatteras Venture Partners typically joins rounds of $2.6M–$50M at Series A, $5M–$82M at Series B and $8M–$88M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hatteras Venture Partners participates in.
How do I contact Hatteras Venture Partners?
Public channels for Hatteras Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hatteras Venture Partners?
The team at Hatteras Venture Partners includes Douglas Reed (General Partner), Jeff Terrell (General Partner) and Myla Lai-Goldman (Venture Partner), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
